Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, announces the appointment of Berndt Modig as Chief Financial Officer (CFO). 

Berndt Modig (51) brings more than 20 years of international experience in company finance to Prosensa. In his previous position as CFO of Jerini AG, a German drug discovery and development company, he managed several financing operations, including the company's IPO on the Frankfurt stock exchange. He also co-ordinated the acquisition of Jerini by Shire. Before this, Berndt was CFO at Surplex AG and Finance Director Europe of Hayward Industrial Products GmbH, a European subsidiary of Hayward Industries Inc. As co-founder and partner in Agra Industria Sprl and investment manager at IMM GmbH he gained experience in private equity. He started his career at Price Waterhouse in the US where he held several positions in the Financial Services Group. Berndt has a Bachelor degree in Business Administration, Economics and German from the University of Lund, Sweden, an MBA from INSEAD, France and is a Certified Public Accountant.

"We continue to build a strong multinational management team at Prosensa to support our growth strategy. With his distinguished track record of successfully building value in the private and public arena, Berndt has the right expertise to help us execute our business objective of becoming a leading provider of therapeutic solutions for rare neuromuscular disorders" said Hans Schikan, CEO of Prosensa.

Commenting on his new appointment, Berndt Modig said: "Prosensa is an exciting biotechnology company with great potential. I look forward to the opportunity of working with the team to create significant value for its shareholders as the company develops into a leading biopharmaceutical company."

About Prosensa - www.prosensa.com
Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1), Huntington's Disease (HD) and Spinal Muscular Atrophy (SMA).

The company has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. Its lead product, PRO051/GSK2402968, aims at restoring dystrophin expression and improving muscle condition and function in a relatively large subpopulation of Duchenne patients and has successfully completed a Phase I/II study. Preparations are ongoing to start enrolling patients in a Phase III study in 2010. PRO044, the company's second product candidate, addresses another subpopulation of Duchenne patients and entered clinical trials in the last quarter of 2009.

Prosensa was founded in 2002 and is located in Leiden, The Netherlands. The company works closely together with Leiden University Medical Center (LUMC) and is supported by a consortium of leading biotech investors, including Abingworth, Life Sciences Partners, GIMV, AGF and MedSciences Capital. In October 2009, Prosensa entered into a strategic alliance with GlaxoSmithKline (GSK) to accelerate and broaden the development of some of its DMD product candidates.

For more information about Prosensa, please visit www.prosensa.com